Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2013-01-22 Capital/Financing Update
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Allied closes SPP, bringing total capital raised to $4.6M 2 pages 268.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated January 23, 2012, reporting the closure of a Share Purchase Plan (SPP) raising $2.9M, combined with a previous placement raising a total of $4.6M. It discusses the use of funds, upcoming milestones, and mentions the lead manager for the placement. There are no financial statements or detailed financial performance data, nor is this a report or presentation. The content focuses on capital raising activities and financing updates. The document length is 3826 characters, which is relatively short but contains substantive information about capital raising, not just a notice or report publication announcement. Therefore, the document fits best under Capital/Financing Update (CAP).
2013-01-22 English
Allied's hernia and pelvic floor results 3 pages 280.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Allied Healthcare Group reporting positive results from a scientific study on their ADAPT-treated tissue used in abdominal hernia and pelvic floor reconstructions. It discusses study outcomes, product advantages, and future commercial prospects. There are no financial statements, regulatory certifications, voting results, or management changes. The content is a corporate announcement about scientific and product development progress rather than a financial report or regulatory filing. The document length is 8888 characters, which is substantial but the content is clearly an announcement of study results and business prospects. Therefore, the best fitting category is a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into other specific categories like Annual Report, Earnings Release, or Investor Presentation.
2013-01-09 English
Appendix 3B and Section 708A(5)(e) Notice 15 pages 727.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form submitted to the Australian Stock Exchange (ASX), which is a standard regulatory form used to announce the issue of new shares by a company. It details the allotment of 85,048,500 shares via a private placement, including specifics about the securities issued, the issue price, and compliance with ASX listing rules. The document is a formal announcement of a capital raising event and share issuance, not a financial report or earnings release. It is not a full report but a regulatory announcement about a capital change. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not a brief notice but a detailed regulatory announcement of a share issue.
2012-12-20 English
Top 20 securityholders 1 page 227.7KB
Major Shareholding Notification Classification · 100% confidence The document lists the twenty largest shareholders of the company along with the number of shares held and percentage of issued capital. It is a straightforward disclosure of major shareholding information without any financial statements, management discussion, or other report content. The document length is short (1477 characters) and contains no indication of being a report or announcement of a report. This matches the definition of a Major Shareholding Notification, which reports changes or details of significant share ownership levels.
2012-12-20 English
Allied announces successful grant for Coridon's HPV vaccine 3 pages 266.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 20 December 2012 from Allied Healthcare Group regarding a grant awarded to Professor Ian Frazer for HPV vaccine development. It discusses the grant details, background on HPV, the company's business focus, and related research programs. There are no financial statements, no quarterly or annual results, no management discussion of financial performance, no voting results, no regulatory certifications, or any other formal report content. The document is a corporate announcement about a grant and research progress, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being published or attached. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2012-12-19 English
Allied Announces Placement and Share Purchase Plan 3 pages 205.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 17 December 2012 from Allied Healthcare Group. It announces the completion of a strategic placement raising $1.7 million and the launch of a share purchase plan (SPP). The content focuses on fundraising activities, use of funds, and details about the share purchase plan including record dates and subscription limits. There is no financial report, earnings data, or management discussion of financial results. The document is clearly an update on capital raising and financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 9186 characters, which is substantial and contains detailed information about the placement and SPP, confirming it is not a brief announcement or a report publication notice.
2012-12-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.